Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

October 31, 2016

Study Completion Date

March 31, 2020

Conditions
Portopulmonary Hypertension
Interventions
DRUG

Ambrisentan

Ambrisentan once-daily in the morning with or without food. The adult dose selected for this study will be 5 mg for the first 4 weeks. After the initial 4 weeks the dose will be increased to 10mg (available doses are 5, and 10 mg) based on tolerance safety. Subjects will remain on 10mg until they complete the study. Dose adjustments may be made based on side effects.

Trial Locations (6)

27599

University of North Carolina, Chapel Hill

32224

Mayo Clinic Florida, Jacksonville

43221

The Ohio State University Medical Center, Columbus

75390

UT Southwestern Medical Center, Dallas

92093

UCSD Medical Center, La Jolla

02111

Tufts Medical Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Tufts Medical Center

OTHER